Home » Stocks » Inspyr Therapeutics

Inspyr Therapeutics, Inc. (NSPX)

Stock Price: $0.140 USD 0.137 (4,566.67%)
Updated Jun 30, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 700,000
Revenue (ttm) n/a
Net Income (ttm) -1.59M
Shares Out 150.00M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jun 30, 2020
Last Price $0.140
Previous Close $0.003
Change ($) 0.137
Change (%) 4,566.67%
Day's Open 0.700
Day's Range 0.050 - 0.700
Day's Volume 226,883
52-Week Range 0.002 - 0.700

More Stats

Market Cap 700,000
Enterprise Value 3.04M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 150.00M
Float 150.00M
EPS (basic) -0.36
EPS (diluted) -0.14
FCF / Share -0.19
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta -15.72
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -522,000
Net Income -1.59M
Free Cash Flow -380,000
Net Cash -2.34M
Net Cash / Share -0.47
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -195.69%
ROE n/a
ROIC 15.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$21.25*
Low
21.3
Current: $0.140
High
21.3
Target: 21.25
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-0.61-0.72-5.85-3.19-6.07-7.00-6.40-6.88-6.32-4.17
Net Income-0.93-0.01-11.10-3.19-5.89-6.99-5.30-6.92-5.71-4.26
Shares Outstanding0.230.030.160.050.040.030.030.020.020.02
Earnings Per Share-4.20-6.60-82.20-91.20-149.70-207.00-189.02-288.03-243.02-225.02
Operating Cash Flow-0.31-0.20-1.09-2.73-4.63-5.04-4.71-4.52-3.74-2.77
Capital Expenditures-------0.01-0.01--
Free Cash Flow-0.31-0.20-1.10-2.73-4.64-5.05-4.72-4.53-3.74-2.77
Cash & Equivalents0.020.330.010.552.472.323.592.355.533.67
Total Debt2.832.602.48--0.110.110.110.110.11
Net Cash / Debt-2.80-2.27-2.470.552.472.213.482.245.433.57
Assets0.020.370.070.732.682.633.892.575.693.86
Liabilities8.758.638.921.624.592.532.633.302.642.57
Book Value-8.72-8.27-8.85-0.89-1.910.101.26-0.733.051.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Inspyr Therapeutics, Inc.
Country United States
CEO Michael Cain

Stock Information

Ticker Symbol NSPX
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: NSPX

Description

Inspyr Therapeutics, Inc., clinical-stage pharmaceutical company, focuses on the development of therapeutics for the treatment of diseases. It focuses on a pipeline of small molecule adenosine receptor modulators, such as A2B antagonists, dual A2A/A2B antagonists, and A2A agonists. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.